Profile data is unavailable for this security.
About the company
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
- Revenue in USD (TTM)11.79m
- Net income in USD-40.29m
- Incorporated2013
- Employees49.00
- LocationJaguar Health Inc200 PINE STREET SUITE 400SAN FRANCISCO 94104United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://jaguar.health/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procyon Corp | 4.98m | -312.97k | 1.53m | 19.00 | -- | 0.7027 | -- | 0.307 | -0.0387 | -0.0387 | 0.6138 | 0.2817 | 1.47 | 2.32 | 9.90 | 262,338.40 | -10.08 | 1.19 | -12.70 | 1.44 | 78.07 | 74.40 | -6.84 | 0.8691 | 2.41 | -- | 0.00 | -- | 6.35 | 3.53 | -367.38 | -- | 17.32 | -- |
| Universe Pharmaceuticals Inc | 17.86m | -3.67m | 1.61m | 216.00 | -- | 0.0287 | -- | 0.0902 | -10.13 | -10.13 | 39.18 | 99.64 | 0.2602 | 5.88 | 1.38 | 82,679.35 | -5.35 | -5.40 | -7.08 | -7.09 | 35.28 | 43.33 | -20.56 | -9.65 | 3.90 | -17.46 | 0.1416 | -- | -22.44 | -10.27 | 57.92 | -- | 46.30 | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 1.90m | 40.00 | -- | -- | -- | 0.6858 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 2.58 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| Bio Essence Corp | 565.67k | -160.45k | 2.08m | 2.00 | -- | -- | -- | 3.67 | -0.0042 | -0.0042 | 0.0149 | -0.0816 | 1.26 | -- | 16.06 | 282,835.00 | -35.64 | -40.94 | -- | -- | 69.28 | 38.36 | -28.36 | -134.00 | -- | -57.42 | -- | -- | -- | -17.08 | -286.98 | -- | -- | -- |
| InVitro International | 716.89k | 6.22k | 2.21m | 16.00 | 284.00 | 3.09 | -- | 3.09 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| PRF Technologies Ltd | 0.00 | -4.09m | 2.32m | 2.00 | 0.0098 | 0.1412 | -- | -- | 301.27 | 301.27 | 0.00 | 20.97 | 0.00 | -- | -- | 0.00 | -57.27 | -71.03 | -118.06 | -84.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.12 | -- | -- | -- |
| Scisparc Ltd | -100.00bn | -100.00bn | 2.59m | 2.00 | -- | -- | -- | -- | -- | -- | -- | -1.46 | -- | -- | -- | -- | -- | -63.15 | -- | -90.87 | -- | -- | -- | -456.81 | 0.5151 | -- | 1.04 | -- | -54.64 | -- | -22.69 | -- | -- | -- |
| SOHM Inc | -100.00bn | -100.00bn | 2.60m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Jaguar Health Inc | 11.79m | -40.29m | 2.87m | 49.00 | -- | 0.7415 | -- | 0.2433 | -54.06 | -54.06 | 12.98 | 1.53 | 0.2184 | 0.2099 | 8.78 | 240,510.20 | -76.04 | -90.27 | -152.77 | -144.36 | 81.92 | 75.33 | -348.22 | -458.25 | 0.5197 | -4.62 | 0.8759 | -- | 19.75 | 15.14 | 6.80 | -- | -- | -- |
| China Pharma Holdings Inc | 4.05m | -3.19m | 3.18m | 224.00 | -- | 0.3825 | -- | 0.7849 | -1.10 | -1.10 | 1.28 | 1.66 | 0.2769 | 2.17 | 14.52 | 18,090.54 | -21.80 | -18.69 | -35.67 | -37.95 | -10.94 | -1.14 | -78.72 | -44.96 | 0.1026 | -30.50 | 0.2884 | -- | -35.41 | -16.15 | -53.84 | -- | 16.49 | -- |
| CYANOTECH CORP | 25.27m | -1.78m | 3.25m | 83.00 | -- | 0.4033 | 17.21 | 0.1287 | -0.2469 | -0.2469 | 3.51 | 1.09 | 1.05 | 2.21 | 12.81 | 304,433.80 | -7.41 | -6.08 | -13.42 | -8.05 | 32.00 | 32.26 | -7.03 | -6.37 | 0.2988 | -1.47 | 0.5089 | -- | 4.96 | -5.36 | 39.19 | -- | 1.97 | -- |
| Functional Brands Inc | 6.80m | -377.56k | 3.44m | 32.00 | -- | 2.47 | -- | 0.5067 | -0.0546 | -0.0546 | 0.9614 | 0.0854 | 0.8873 | 0.3527 | 37.24 | 212,408.80 | -4.93 | -- | -9.96 | -- | 91.06 | -- | -5.55 | -- | 0.4419 | -0.8723 | 0.6346 | -- | -3.72 | -- | 54.93 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Jaguar Health Inc's reporting currency: US Dollar USD
1.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2025 | 24.05k | 0.64% |
| DRW Securities LLCas of 31 Dec 2025 | 17.82k | 0.48% |
| UBS Securities LLCas of 31 Dec 2025 | 6.40k | 0.17% |
| Tower Research Capital LLCas of 30 Sep 2025 | 3.38k | 0.09% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 702.00 | 0.02% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 220.00 | 0.01% |
| Leonteq Securities AGas of 31 Dec 2025 | 188.00 | 0.01% |
| International Assets Investment Management LLCas of 31 Dec 2025 | 45.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 14.00 | 0.00% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
